Evidence of predisposing epimutation in retinoblastoma

Hum Mutat. 2019 Feb;40(2):201-206. doi: 10.1002/humu.23684. Epub 2018 Nov 26.

Abstract

Retinoblastoma (RB), which represents the most common childhood eye cancer, is caused by biallelic inactivation of RB1 gene. Promoter hypermethylation is quite frequent in RB tissues but conclusive evidence of soma-wide predisposing epimutations is currently scant. Here, 50 patients who tested negative for RB1 germline sequence alterations were screened for aberrant promoter methylation using methylation-specific MLPA. The assay, performed on blood, identified a sporadic patient with methylation of CpG106, absent in parents' DNA. Bisulfite pyrosequencing accurately quantified CpG methylation in blood DNA (mean ∼49%) and also confirmed the aberration in DNA isolated from oral mucosa although at lower levels (mean ∼34%). Using a tag-SNP, methylation was demonstrated to affect the maternal allele. Real-time qPCR demonstrated RB1 transcriptional silencing. In conclusion, we documented that promoter methylation can act as the first "hit" in Knudson's model. This mosaic epimutation mimics the effect of an inactivating mutation and phenocopies RB onset.

Keywords: epimutation; gene silencing; mosaicism; promoter methylation; retinoblastoma.

MeSH terms

  • Alleles
  • DNA Methylation / genetics*
  • Epigenesis, Genetic
  • Female
  • Gene Silencing
  • Genetic Predisposition to Disease*
  • Humans
  • Infant
  • Male
  • Mutation / genetics
  • Polymorphism, Single Nucleotide / genetics
  • Promoter Regions, Genetic
  • Retinoblastoma / genetics*
  • Retinoblastoma / pathology
  • Retinoblastoma Binding Proteins / genetics*
  • Ubiquitin-Protein Ligases / genetics*

Substances

  • RB1 protein, human
  • Retinoblastoma Binding Proteins
  • Ubiquitin-Protein Ligases